Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07515924 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Oral Gallium Maltolate for Recurrent Glioblastoma

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Sep 2027 → Mar 2028
See other at-risk trials from Medical College of Wisconsin

Record History

  1. Start date: Jun 2026 to Mar 2027 Primary and study completion pushed from Sep 2027 to Mar 2028 · Eligibility criteria expanded, about 21 words · Site details revised Show 3 more changesShow less
    • Primary and study completion pushed from Sep 2027 to Mar 2028
    • Eligibility criteria expanded, about 21 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 0 investigational study to assess the central nervous system penetration and tumoral concentration of gallium in patients with recurrent glioblastoma administered with preoperative gallium maltolate.
Trial Details
NCT Number NCT07515924
Lead Sponsor Medical College of Wisconsin
Conditions Glioblastoma
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov